Literature DB >> 31876630

Comorbidities in gout and hyperuricemia: causality or epiphenomena?

Nicholas A Sumpter1, Kenneth G Saag2, Richard J Reynolds2, Tony R Merriman1.   

Abstract

PURPOSE OF REVIEW: To review advances in the understanding of potentially causal relationships between gout, hyperuricemia and comorbidities. RECENT
FINDINGS: Observational studies reveal 4-5 comorbidity clusters in gout patients. There tend to be gout alone, gout with chronic kidney disease and gout with other metabolic comorbidities. However, heterogeneous study populations and confounding make inference difficult for causal relationships. Mendelian randomization leverages genetic information as an instrumental variable to indicate putatively causal relationships between traits of epidemiological interest. Thus far, Mendelian randomization has not indicated widespread causal relationships of serum urate for comorbid traits. However, BMI has a small causal effect on serum urate, which may partially explain the increased prevalence of metabolic syndrome and cardiovascular disease among those with gout and hyperuricemia. There is a lack of robust and sufficiently powered Mendelian randomization studies for many serum urate-associated traits, such as hypertension. No adequately powered studies have been completed for gout and its comorbidities.
SUMMARY: Although observational studies indicate putative causal effects of serum urate on comorbidities, Mendelian randomization studies suggest that serum urate does not have a causal role on the various tested comorbidities. There remains work to be done in clarifying the causal role of gout per se on the same traits.

Entities:  

Mesh:

Substances:

Year:  2020        PMID: 31876630     DOI: 10.1097/BOR.0000000000000691

Source DB:  PubMed          Journal:  Curr Opin Rheumatol        ISSN: 1040-8711            Impact factor:   5.006


  8 in total

1.  Taxifolin blocks monosodium urate crystal-induced gouty inflammation by regulating phagocytosis and autophagy.

Authors:  Mei-Hua Piao; Hui Wang; Yin-Jing Jiang; Yan-Ling Wu; Ji-Xing Nan; Li-Hua Lian
Journal:  Inflammopharmacology       Date:  2022-06-16       Impact factor: 5.093

Review 2.  Excess comorbidities in gout: the causal paradigm and pleiotropic approaches to care.

Authors:  Hyon K Choi; Natalie McCormick; Chio Yokose
Journal:  Nat Rev Rheumatol       Date:  2021-12-17       Impact factor: 32.286

3.  Prevalence of Hypertension in Sudanese Patients With Gouty Arthritis.

Authors:  Sufian M Khaild; Amro M Fagir; Ziryab I Taha; Awadelkareem A Elshareef; Mohammed H Mohammed; Khalda M Saeed; Elnour M Elagib; Elwalied M Ibrahim; Jimmy William
Journal:  Cureus       Date:  2022-04-18

4.  Genetic correlations between traits associated with hyperuricemia, gout, and comorbidities.

Authors:  Richard J Reynolds; M Ryan Irvin; S Louis Bridges; Hwasoon Kim; Tony R Merriman; Donna K Arnett; Jasvinder A Singh; Nicholas A Sumpter; Alexa S Lupi; Ana I Vazquez
Journal:  Eur J Hum Genet       Date:  2021-02-26       Impact factor: 5.351

5.  Presence of tophi is associated with a rapid decline in the renal function in patients with gout.

Authors:  Yoon-Jeong Oh; Ki Won Moon
Journal:  Sci Rep       Date:  2021-03-11       Impact factor: 4.379

6.  Uricase-deficient rats with similarly stable serum uric acid to human's are sensitive model animals for studying hyperuricemia.

Authors:  Yinfang Gao; Yun Yu; Wan Qin; Nan Fan; Yalin Qi; Huan Chen; Weigang Duan
Journal:  PLoS One       Date:  2022-03-03       Impact factor: 3.240

Review 7.  Genetics of hyperuricemia and gout: Insights from recent genome-wide association studies and Mendelian randomization studies.

Authors:  Yu-Lin Ko
Journal:  Tzu Chi Med J       Date:  2021-11-24

8.  Medical Students' Perspective and Knowledge of Asymptomatic Hyperuricemia and Gout Management: A Cross-Sectional Study.

Authors:  Sanja Zuzic Furlan; Doris Rusic; Marko Kumric; Josko Bozic; Marino Vilovic; Tina Vilovic; Marko Rada; Venija Cerovecki; Marion Tomicic
Journal:  Healthcare (Basel)       Date:  2021-11-26
  8 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.